Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

With an approval being a binary decision, there is always risk, despite Nasrat once claiming that the FDA can’t stop Elite. Well, yes, yes they can.

The stock price would take a hit if Vyvanse isn’t approved, but I think it would only be temporary. Is the issue fixable, what’s the timing, etc.

With just the known drugs that we know will launch over the next couple quarters, without Vyvanse, I would value Elite closer to $0.60 once they launch and start getting traction and capturing market share over the next several quarters.